True Drug Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 29-05-2024
- Paid Up Capital ₹ 0.10 M
as on 29-05-2024
- Company Age 4 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 23.38%
(FY 2022)
- Profit 71.21%
(FY 2022)
- Ebitda 70.77%
(FY 2022)
- Net Worth -29.34%
(FY 2022)
- Total Assets -8.17%
(FY 2022)
About True Drug
The Company is engaged in the Business Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Sureshkumar Gondalia, Hriday Gondalia, and Shambhubhai Gondalia serve as directors at the Company.
- CIN/LLPIN
U74999GJ2020PTC114873
- Company No.
114873
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Jul 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Surat, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at True Drug?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sureshkumar Gondalia  | Director | 21-Jul-2020 | Current |
Hriday Gondalia  | Director | 23-Jul-2022 | Current |
| Shambhubhai Gondalia | Director | 21-Jul-2020 | Current |
Financial Performance of True Drug.
True Drug Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 23.38% increase. The company also saw a substantial improvement in profitability, with a 71.21% increase in profit. The company's net worth observed a substantial decline by a decrease of 29.34%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of True Drug?
Unlock access to True Drug's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Aalidhra Realty Private LimitedActive 35 years 8 monthsSureshkumar Gondalia, Hriday Gondalia and 1 more are mutual person
- Gokulanand Polytech Private LimitedActive 34 years 5 months
Sureshkumar Gondalia, Hriday Gondalia and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at True Drug?
True Drug has a workforce of 0 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of True Drug, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped True Drug's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
